Published:
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund
XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 percentage points.
Biotech’s strength is likely to continue — so it’s not too late for investors to get in, sector analysts say.
Related
Opinion: Biotech is back. Here’s why these rallying stocks belong in your portfolio now.
Published:
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund
XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 percentage points.
Biotech’s strength is likely to continue — so it’s not too late for investors to get in, sector analysts say.
Share this:
Related